Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from OncoSil Medical Ltd ( (AU:OSL) ).
OncoSil Medical Limited has announced that its Annual General Meeting will be held on November 19, 2025, in Melbourne, with the deadline for director nominations set for October 1, 2025. This announcement is significant for stakeholders as it outlines the company’s governance timeline and provides an opportunity for shareholder engagement. Further details about the AGM will be shared in the Notice of Meeting, highlighting the company’s commitment to transparency and shareholder communication.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
More about OncoSil Medical Ltd
OncoSil Medical Limited is a global medical device company specializing in Interventional Oncology. The company aims to enhance cancer treatment outcomes through the intratumoural placement of Phosphorous-32 Microparticles alongside chemotherapy. OncoSil Medical has developed the OncoSil™ device for treating unresectable locally advanced pancreatic cancer, allowing for higher radiation doses directly into tumors while sparing surrounding organs. The device has received CE Marking approval and is designated as a breakthrough device in Europe and the United States, with approval for sale in over 30 countries.
Average Trading Volume: 42,116
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$32.29M
See more insights into OSL stock on TipRanks’ Stock Analysis page.